Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Factors associated with progression of diabetic nephropathy in Japanese elderly patients with type 2 diabetes: sub-analysis of the Japanese Elderly Diabetes Intervention Trial.

Araki S, Nishio Y, Araki A, Umegaki H, Sakurai T, Iimuro S, Ohashi Y, Uzu T, Maegawa H, Kashiwagi A, Ito H; Japanese Elderly Intervention Trial Research Group.

Geriatr Gerontol Int. 2012 Apr;12 Suppl 1:127-33. doi: 10.1111/j.1447-0594.2011.00820.x.

PMID:
22435948
2.

Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design.

Shikata K, Haneda M, Koya D, Suzuki Y, Tomino Y, Yamada K, Maeda S, Kawakami N, Uzu T, Nishimura M, Sato C, Ogawa D, Makino H; DNETT-Japan Study Group.

Diabetes Res Clin Pract. 2010 Feb;87(2):228-32. doi: 10.1016/j.diabres.2009.09.025. Epub 2009 Nov 4.

PMID:
19889469
3.

Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study.

Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, Cavallo Perin P; Casale Monferrato Study.

Diabetes Care. 2003 Jul;26(7):2150-5.

PMID:
12832328
4.

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M.

Diabetes Res Clin Pract. 1995 May;28(2):103-17.

PMID:
7587918
5.

Silent cerebral infarction is associated with the development and progression of nephropathy in patients with type 2 diabetes.

Bouchi R, Babazono T, Yoshida N, Nyumura I, Toya K, Hayashi T, Hanai K, Tanaka N, Ishii A, Iwamoto Y.

Hypertens Res. 2010 Oct;33(10):1000-3. doi: 10.1038/hr.2010.122. Epub 2010 Jul 8.

PMID:
20613763
6.

Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.

Mann JF, Gerstein HC, Yi QL, Franke J, Lonn EM, Hoogwerf BJ, Rashkow A, Yusuf S; HOPE Investigators.

Am J Kidney Dis. 2003 Nov;42(5):936-42.

PMID:
14582037
7.

Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy.

Fujita H, Morii T, Koshimura J, Ishikawa M, Kato M, Miura T, Sasaki H, Narita T, Ito S, Kakei M.

Endocr J. 2006 Dec;53(6):745-52. Epub 2006 Sep 12.

8.

Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes.

Zoppini G, Targher G, Chonchol M, Perrone F, Lippi G, Muggeo M.

Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):580-6. doi: 10.1016/j.numecd.2008.11.003. Epub 2009 Feb 3.

PMID:
19196499
9.

Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients.

Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R.

Diabetes Care. 1998 Jan;21(1):116-20.

PMID:
9538981
11.

Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria.

Song KH, Ko SH, Kim HW, Ahn YB, Lee JM, Son HS, Yoon KH, Cha BY, Lee KW, Son HY.

Diabetes Care. 2005 Jul;28(7):1718-23.

PMID:
15983325
12.

Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia.

Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R.

Arch Intern Med. 1998 May 11;158(9):998-1004.

PMID:
9588433
13.

Gender differences in the association between HDL cholesterol and the progression of diabetic kidney disease in type 2 diabetic patients.

Hanai K, Babazono T, Yoshida N, Nyumura I, Toya K, Hayashi T, Bouchi R, Tanaka N, Ishii A, Iwamoto Y.

Nephrol Dial Transplant. 2012 Mar;27(3):1070-5. doi: 10.1093/ndt/gfr417. Epub 2011 Jul 22.

PMID:
21785041
14.
15.

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.

Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group.

Arch Intern Med. 2003 Jul 14;163(13):1555-65.

PMID:
12860578
16.

Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus.

Gambaro G, Bax G, Fusaro M, Normanno M, Manani SM, Zanella M, Dangelo A, Fedele D, Favaro S.

Diabetes Nutr Metab. 2001 Dec;14(6):337-42.

PMID:
11853366
17.

Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria.

Okada T, Nagao T, Matsumoto H, Nagaoka Y, Wada T, Nakao T.

Nephrology (Carlton). 2012 Jan;17(1):68-75. doi: 10.1111/j.1440-1797.2011.01525.x.

PMID:
21933307
18.

Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.

Abdin AA, Hassanien MA, Ibrahim EA, El-Noeman Sel-D.

J Diabetes Complications. 2010 Sep-Oct;24(5):325-33. doi: 10.1016/j.jdiacomp.2009.04.001. Epub 2009 Jun 23.

PMID:
19553142
19.

Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy.

Chen J, Gall MA, Yokoyama H, Jensen JS, Deckert M, Parving HH.

Diabetes Care. 1996 Feb;19(2):130-4.

PMID:
8718432
20.

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS.

Control Clin Trials. 1999 Oct;20(5):493-510.

PMID:
10503809

Supplemental Content

Support Center